Contrasting Henry Schein (HSIC) & Its Rivals

Henry Schein (NASDAQ:HSIC – Get Free Report) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it contrast to its rivals? We will compare Henry Schein to similar companies based on the strength of its profitability, dividends, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Ratings

This is a breakdown of current recommendations for Henry Schein and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Henry Schein 1 5 8 0 2.50
Henry Schein Competitors 1890 7762 13426 840 2.55

Henry Schein presently has a consensus price target of $93.86, indicating a potential upside of 12.45%. As a group, “Healthcare Providers & Services” companies have a potential upside of 22.03%. Given Henry Schein’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Henry Schein has less favorable growth aspects than its rivals.

Risk & Volatility

Henry Schein has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Henry Schein’s rivals have a beta of 0.98, indicating that their average share price is 2% less volatile than the S&P 500.

Profitability

This table compares Henry Schein and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Henry Schein 3.07% 16.39% 5.58%
Henry Schein Competitors 1.61% -135.40% -1.32%

Valuation and Earnings

This table compares Henry Schein and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Henry Schein $13.18 billion $398.00 million 22.87
Henry Schein Competitors $21.13 billion $301.67 million -3.54

Henry Schein’s rivals have higher revenue, but lower earnings than Henry Schein. Henry Schein is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 0.9% of Henry Schein shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Henry Schein beats its rivals on 7 of the 13 factors compared.

Henry Schein Company Profile

(Get Free Report)

Henry Schein, Inc. is a global distributor of health care products and services, serving dental and medical practitioners, veterinary professionals, and other health care organizations. The company traces its roots to a pharmacy founded by Henry and Esther Schein in Queens, New York, in 1932. Its offerings include medical and dental supplies, equipment, pharmaceuticals, vaccines, and diagnostic products. Henry Schein also provides practice-management software, technology solutions, and business services designed to help health care professionals manage their operations.

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.